A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome

Journal of Virological Methods

Volumn 184, Issue 1-2, 2012, Pages 93-97

  Moreira, Simone ^a   Garcia, Raquel Francine Liermann ^a   Gutberlet, Andréia ^a   Bertol, Bruna Cristina ^a   Ferreira, Leslie Ecker ^a   de Souza Leite Pinho, Mauro ^a   de França, Paulo Henrique Condeixa ^a  

^a UNIVERSITY OF JOINVILLE REGION   (Brazil)

Author keywords

Hepatitis C; IL28B; PCR RFLP; Single Nucleotide Polymorphism

Indexed keywords

ENDONUCLEASE; OLIGONUCLEOTIDE;

ALLELE; AMPLICON; ANALYTICAL PARAMETERS; ARTICLE; BSRDI GENE; GENE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS B; HPY166II GENE; IL28B GENE; NONHUMAN; ONLINE ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RELIABILITY; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; THERMODYNAMICS; TREATMENT OUTCOME; VALIDATION PROCESS;

ANTIVIRAL AGENTS; DNA PRIMERS; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84863835379     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.05.024     Document Type: Article

References (39)

1. Akkarathamrongsin S., Sugiyama M., Matsuura K., Kurbanov F., Poovorawan Y., Tanaka Y., Mizokami M. High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatology Research 2010, 40:956-962.
2. Altschul S.F., Madden T.L., Schäffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Research 1997, 25:3389-3402.
3. Aparicio E., Parera M., Franco S., Pérez-Alvarez N., Tural C., Clotet B. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010, 5:e13771.
4. Asselah T., De Muynck S., Bröet P., Masliah-Planchon J., Blanluet M., Bièche I., Lapalus M., Martinot-Peignoux M., Lada O., Estralaud E., Zhang Q., El Ray A., Vidaud D., Ripault M., Boyer N., Bedossa P., Valla D., Vidaud M., Marcellin P. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of Hepatology 2012, 56:527-532.
5. Caetano A.R. Marcadores SNP: conceitos básicos, aplicações no manejo e no melhoramento animal e perspectivas para o futuro. Revista Brasileira de Zootecnia 2009, 38:64-71.
6. Charlton M.R., Thompson A., Veldt B.J., Watt K., Tillmann H., Poterucha J.J., Heimbach J.K., Goldstein D., McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53:317-324.
7. Entrez SNP. Available from: (accessed 07.07.11). http://www.ncbi.nlm.nih.gov/snp.
8. Feld J.J., Nanda S., Huang Y., Chen W., Cam M., Pusek S.N., Schweigler L.M., Theodore D., Zacks S.L., Liang T.J., Fried M.W. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007, 46:1548-1563.
9. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., Uchiyama H., Soejima Y., Shirabe K., Matsuura Y., Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139:1577-1585.
10. Galmozzi E., Menico B.D., Rametta R., Dongiovanni P., Fracanzani A.L., Benedan L., Borroni V., Maggioni P., Fargion S., Valenti L. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis 2011, 18:628-630.
11. Garcia S.L., Coto-Llerena M., Gallart S.P.P., Bernhardt X.F. Genética y tratamento de la hepatites C: hacia um tratamento personalizado?. Gastroenterologia y Hepatologia 2011, 34:352-360.
12. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heizen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchinson J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 462:399-401.
13. Georgel P., Schuster C., Zeisel M.B., Stoll-Keller F., Berg T., Bahram S., Baumert T.F. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends in Molecular Medicine 2010, 16:277-286.
14. Guirgis B.S.S., Abbas R.O., Azzazy H.M.E. Hepatitis B virus genotyping: current methods and clinical implications. International Journal of Infectious Diseases 2010, 14:e941-e953.
15. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series 1999, 41:95-98. http://www.mbio.ncsu.edu/BioEdit/bioedit.html.
16. Hashemi M., Moazeni-Roodi A., Bahari A., Taheri M.A. Tetra-primer amplification refractory mutation system-polymerase chain reaction for the detection of rs8099917 IL28B genotype. Nucleosides, Nucleotides & Nucleic Acids 2012, 31:55-60.
17. Karino Y., Ozeki I., Toyota J., Imamura M., Tsuge M., Chayama K., Sezaki H., Akuta N., Kumada H. IL28B genotype major and relapse of previous PEG-IFN/RBV therapy are the convincing predictor of sustained virological response in telaprevir with PEG-IFN/RBV therapy. Journal of Hepatology 2011, 54:s525.
18. Kau A., Vermehren J., Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology 2008, 49:634-651.
19. Ladero J.M., Martin E.G., Fernández C., Carballo M., Devesa J., Matínez C., Suárez A., Díaz-Rubio M., Agúndez J.A. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data. Journal of Gastroenterology and Hepatology 2011, 10.1111/j.1440-1746.2011.06834.x.
20. Lindh M., Lagging M., Arnholm B., Eilard A., Nilsson S., Norkrans J., Söderholm J., Wahlberg T., Wejstal R., Westin J., Hellstrand K. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Journal of Viral Hepatitis 2011, 18:325-331.
21. McCarthy J.J., Li J.H., Thompson A., Suchindran S., Lao X.Q., Patel K., Tillmann H.L., Muir A.J., McHutchison J.G. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
22. Montes-cano M.A., García-Lozano J.R., Abad-Molina C., Romero-Gómez M., Barroso N., Aguilar-Reina J., Núñez-Róldan A., González-Escribano M.F. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
23. Novais C.M., Pires-Alves M. PCR em Tempo Real: uma inovação tecnológica da Reação em Cadeia da Polimerase. Revista Biotecnologia Ciência e Desenvolvimento 2004, ed. 3:10-13.
24. Ota M., et al. Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism. Nature Protocols 2007, 2:2857-2864.
25. Poordad F., Bronowicki P., Gordon S.C., Zeuzem S., Jacobson I.M., Sulkowski M.S., Poynard T., Morgan T.R., Burroughs M., Sniukiene V., Boparai N., Brass C.A., Albrecht J.K., Bacon B.R. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. Journal of Hepatology 2011, 54:s6.
26. Rallón N., Soriano V., Naggie S., Restrepo C., McHutchison J., Vispo E., Benito J.M. Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. Journal of Antimicrobial Chemotherapy 2012, 10.1093/jac/dkr598.
27. Rauch A., Kutalik Z., Descombes P., Cai T., Di Lulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Günthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Müllhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a Genome-Wide Association Study. Gastroenterology 2010, 138:1338-1345.
28. Roberts R.J., Vincze T., Posfai J., Macelis D. Rebase: a database for DNA restriction and modification: enzymes, genes and genomes. Nucleic Acids Research 2010, 38:234-236.
29. Rozen S., Skaletsky H.J. Primer 3 on the www for general user and for biologist programmers. Methods in Molecular Biology 2000, 365-386. Humana Press, Totowa, NJ. S. Krawets, S. Misener (Eds.).
30. Sarazin-filipowicz M., Oakeley E.J., Duong F.H.T., Christen V., Terracciano L., Filipowicz W., Heim M.H. Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:7034-7039.
31. Sinn D.H., Kim Y.J., Lee S.T., Gwak G.Y., Choi M.S., Lee J.H., Koh K.C., Yoo B.C., Palk S.W. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. Journal of Gastroenterology and Hepatology 2011, 26:1374-1379.
32. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Müller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B associated with response to chronic hepatitis C response to interferon-α and ribavirin therapy. Nature Genetics 2009, 41:1100-1104.
33. Tai A.W., Chung R.T. Treatment failure in hepatitis C: mechanisms of non-response. Journal of Hepatology 2009, 50:412-420.
34. Tanaka Y., Nishida N., Sugyiama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association IL28B with the response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009, 41:1105-1109.
35. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'hUigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
36. Thompson J.D., Higgins D.G., Gibson T.J. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research 1994, 22:4673-4680.
37. Tsubota A., Fujise K., Namiki Y., Tada N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World Journal of Gastroenterology 2011, 17:419-432.
38. Vincze T., Posfai J., Roberts R.J. NEBcutter: a program to cleave DNA with restriction enzymes. Nucleic Acids Research 2003, 31:3688-3691.
39. WHO - World Health Organization. Hepatitis C Virus. Available from: (accessed 07.07.11). http://www.who.int/mediacentre/factsheets/fs164/en/.